-Novast's Story

Novast's rapid rise in BioSpark

Novast Pharmaceutical has successfully filed over 50 high end drug applications with with the U.S. FDA, with 44 different formulations approved— including 3 technically complex controlled release products. It achieved a breakthrough as the first Chinese drugmaker to enter the mainstream U.S. prescription market, several of these hold leading market shares in the United States.

Since 2021, six of the company’s in-house developed and manufactured high-end formulations, registered concurrently for both the U.S. and Chinese markets, have been approved by China’s NMPA for domestic production and sales.

Dr. Guohua Zhang
CEO of Novast

Founded in 2005 in Nantong, Jiangsu by Dr. Zhang and his technical management team, Novast specializes in drug delivery systems and controlled-release technonolgies.

Each year, the company supplies over 2 billion oral tablets and 176 million capsules to patients worldwide.